To evaluate the efficacy and safety of mirabegron in patients with neurogenic detrusor overactivity due to SCI or MS.
A comprehensive search of the Pubmed, Cochrane, Scopus, and Embase databases was performed. Studies evaluating adult patients with neurogenic detrusor overactivity due to SCI or MS were analyzed according to clinical and urodynamic outcome parameters.
A total of 488 patients were included in 11 studies, with sample sizes ranging from 15 to 91. The duration of the treatments varied from 4 weeks to 12 months. Mirabegron was used as a secondline treatment after anticholinergics in most of the studies. While clinical outcome parameters are used in studies involving only MS patients, urodynamic outcome parameters are also used in studies involving patients with SCI. The efficacy of mirabegron was found not to be different than anticholinergics when compared in MS patients. Comprehensive urodynamic evaluation was performed in 2 randomized, double-blind, placebo-controlled studies and no satisfactory results were obtained compared to placebo. In retrospective studies there were some significant improvements in Pdet(max), MCC and compliance. The major safety concern with mirabegron is cardiovascular safety. In one study, tachyarrhythmia and palpitations reported in a patient with SCI at C6 level, in another study tachycardia reported in one patient with MS.
Although mirabegron demonstrates similar clinical efficacy to anticholinergics in MS patients, its effect on urodynamic parameters in patients with SCI cannot be considered satisfactory. It has a good safety profile with mild cardiovascular side effects.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
All data generated or analysed during this study are included in this published article (and its Supplementary Information file).
Fowler CJ, Dalton C, Panicker JN. Review of neurologic diseases for the urologist. Urol Clin North Am. 2010;37:517–26.
Mete UK, Powell CR. Review of current neurogenic bladder best practices and international guidelines. Curr Bladder Dysfunct Rep. 2020;15:283–95.
Cooley LF, Kielb S. A review of botulinum toxin a for the treatment of neurogenic bladder. Pmr. 2019;11:192–200.
Kashyap M, Tyagi P. The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013;9:617–27.
El Helou E, Labaki C, Chebel R, El Helou J, Abi Tayeh G, Jalkh G, et al. The use of mirabegron in neurogenic bladder: a systematic review. World J Urol. 2020;38:2435–42.
Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54:78–82.
Welk B, Hickling D, McKibbon M, Radomski S, Ethans K. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2018;37:2810–7.
Krhut J, Borovička V, Bílková K, Sýkora R, Míka D, Mokriš J, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37:2226–33.
Zachariou A, Filiponi M, Baltogiannis D, Giannakis J, Dimitriadis F, Tsounapi P, et al. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol. 2017;24:9107–13.
Chen SF, Kuo HC. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. Low Urin Tract Symptoms. 2019;11:O53–8.
Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. Low Urin Tract Symptoms. 2019;11:O65–70.
Park JS, Lee YS, Lee CN, Kim SH, Kim SW, Han SW. Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. 2019;37:1665–70.
Stohrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56:81–8.
Madersbacher H, Murtz G, Stohrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51:432–41.
Przydacz M, Chlosta P, Corcos J. Recommendations for urological follow-up of patients with neurogenic bladder secondary to spinal cord injury. Int Urol Nephrol. 2018;50:1005–16.
Kreydin E, Welk B, Chung D, Clemens Q, Yang C, Danforth T, et al. Surveillance and management of urologic complications after spinal cord injury. World J Urol. 2018;36:1545–53.
Zhang D, Sun F, Yao H, Bao X, Wang D, Cui Y, et al. The efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction: a systematic review and meta-analysis. Front Pharmacol. 2021;12:756582.
Cho SY, Jeong SJ, Lee S, Kim J, Lee SH, Choo MS, et al. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson’s disease: a double-blind, randomized placebo-controlled trial (Parkinson’s Disease Overactive bladder Mirabegron, PaDoMi Study). Neurourol Urodyn. 2021;40:286–94.
Brucker BM, Kalra S. Parkinson’s disease and its effect on the lower urinary tract: evaluation of complications and treatment strategies. Urol Clin North Am. 2017;44:415–28.
Gray R, Stern G, Malone-Lee J. Lower urinary tract dysfunction in Parkinson’s disease: changes relate to age and not disease. Age Ageing. 1995;24:499–504.
Vurture G, Peyronnet B, Palma JA, Sussman RD, Malacarne DR, Feigin A, et al. Urodynamic mechanisms underlying overactive bladder symptoms in patients with Parkinson disease. Int Neurourol J. 2019;23:211–8.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
Glykas I, Fragkoulis C, Mitsikostas DD, Papatsoris A, Mitsogiannis I, Papadopoulos G, et al. B3 agonists or anticholinergics in the treatment of the lower urinary tract dysfunction in patients with multiple sclerosis? A randomized study. World J Urol. 2021;39:3049–56.
Vasudeva P, Prasad V, Yadav S, Kumar N, Saurav K, Prashanth YM, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity resulting from traumatic spinal cord injury: a prospective study. Neurourol Urodyn. 2021;40:666–71.
Trbovich M, Romo T, Polk M, Koek W, Kelly C, Stowe S, et al. The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: an open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy. Spinal Cord Ser Cases. 2021;7:50.
Brucker BM, Jericevic D, Rude T, Enemchukwu E, Pape D, Rosenblum N, et al. Mirabegron versus Solifenacin in multiple sclerosis patients with overactive bladder symptoms: a prospective comparative nonrandomized study. Urology. 2020;145:94–9.
Krebs J, Pannek J, Rademacher F, Wöllner J. Real-world effects of mirabegron in patients with chronic neurogenic detrusor overactivity—a retrospective cohort study. Res Rep Urol. 2020;12:187–92.
Han SH, Cho IK, Jung JH, Jang SH, Lee BS. Long-term efficacy of mirabegron add-on therapy to antimuscarinic agents in patients with spinal cord injury. Ann Rehabil Med. 2019;43:54–61.
Krhut J, Wohlfahrt P, Pudich J, Kufová E, Borovička V, Bílková K, et al. Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity. Int Urol Nephrol. 2021;53:1089–95.
McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126:205–9.
Hadiji N, Previnaire JG, Benbouzid R, Robain G, Leblond C, Mieusset R, et al. Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients? Spinal Cord. 2014;52:701–5.
Yamano Y, Sato T. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Front Microbiol. 2012;3:389.
The author declares no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Akkoc, Y. Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review. Spinal Cord 60, 854–861 (2022). https://doi.org/10.1038/s41393-022-00853-3